(2R,4aS,5R,10bS)-2-((1H-1,2,4-triazol-1-yl)methyl)-5-phenyl-9-(trifluoromethyl)-3,4,4a,5,6,10b-hexahydro-2H-pyrano[3,2-c]quinoline | 858667-81-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: (2R,4aS,5R,10bS)-2-((1H-1,2,4-triazol-1-yl)methyl)-5-phenyl-9-(trifluoromethyl)-3,4,4a,5,6,10b-hexahydro-2H-pyrano[3,2-c]quinoline
• 英文别名: (2R,4aS,5R,10bS)-5-phenyl-2-(1,2,4-triazol-1-ylmethyl)-9-(trifluoromethyl)-3,4,4a,5,6,10b-hexahydro-2H-pyrano[3,2-c]quinoline
• CAS: 858667-81-9
• 化学式: C₂₂H₂₁F₃N₄O
• 分子量: 414.43
• InChiKey: INUKTASUMGDABV-SEONNTABSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  30
• 可旋转键数：
  3
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  52
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  1H-1,2,4-三唑 、 [(2R,4aS,5R,10bS)-5-phenyl-9-(trifluoromethyl)-3,4,4a,5,6,10b-hexahydro-2H-pyrano[3,2-c]quinolin-2-yl]methyl methanesulfonate 以 N-甲基吡咯烷酮 为溶剂， 反应 15.0h， 生成 (2R,4aS,5R,10bS)-2-((1H-1,2,4-triazol-1-yl)methyl)-5-phenyl-9-(trifluoromethyl)-3,4,4a,5,6,10b-hexahydro-2H-pyrano[3,2-c]quinoline
  参考文献：
  名称：

  The discovery and optimization of hexahydro-2H-pyrano[3,2-c]quinolines (HHPQs) as potent and selective inhibitors of the mitotic kinesin-5

  摘要：

  Here we describe the discovery and optimization of hexahydro-2H-pyrano[3,2-c]quinolines (HHPQs) as potent and selective inhibitors of the mitotic kinesin-5 originally found during a high-throughput screening (HTS) campaign sampling our in-house compound collection. The compounds optimized subsequently and characterized herein were potently inhibiting the ATPase activity of Kinesin-5 and also exhibited consistent cellular activity, in that cells arrested in mitosis and apoptosis induction could be observed. X-ray crystallographic data demonstrated that these inhibitors bind in an allosteric pocket of Kinesin-5 distant from the nucleotide and microtubule binding sites. The selected clinical candidate EMD 534085 caused strong growth inhibition in human tumor xenograft models using Colo 205 colon carcinoma cells at doses below 30 mg/kg administered twice weekly without showing severe toxicity as determined by loss of body weight. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.01.110

文献信息

• 2-(Hetero)-aryl substituted tetrahydrochinoline
  申请人：Schiemann Kai

  公开号：US20070203167A1

  公开（公告）日：2007-08-30

  Compounds of the formula I, in which W, R, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 and R 7 have the meanings indicated in Claim 1 , can be employed, inter alia, for the treatment of tumours
• US7868172B2
  申请人：——

  公开号：US7868172B2

  公开（公告）日：2011-01-11
• The discovery and optimization of hexahydro-2H-pyrano[3,2-c]quinolines (HHPQs) as potent and selective inhibitors of the mitotic kinesin-5
  作者：Kai Schiemann、Dirk Finsinger、Frank Zenke、Christiane Amendt、Thorsten Knöchel、David Bruge、Hans-Peter Buchstaller、Ulrich Emde、Wolfgang Stähle、Soheila Anzali

  DOI：10.1016/j.bmcl.2010.01.110

  日期：2010.3

  Here we describe the discovery and optimization of hexahydro-2H-pyrano[3,2-c]quinolines (HHPQs) as potent and selective inhibitors of the mitotic kinesin-5 originally found during a high-throughput screening (HTS) campaign sampling our in-house compound collection. The compounds optimized subsequently and characterized herein were potently inhibiting the ATPase activity of Kinesin-5 and also exhibited consistent cellular activity, in that cells arrested in mitosis and apoptosis induction could be observed. X-ray crystallographic data demonstrated that these inhibitors bind in an allosteric pocket of Kinesin-5 distant from the nucleotide and microtubule binding sites. The selected clinical candidate EMD 534085 caused strong growth inhibition in human tumor xenograft models using Colo 205 colon carcinoma cells at doses below 30 mg/kg administered twice weekly without showing severe toxicity as determined by loss of body weight. (C) 2010 Elsevier Ltd. All rights reserved.